References
- Anderson D, Reed S, Lintemoot J, et al. A first look at duloxetine (Cymbalta®) in a postmortem laboratory. J Anal Toxicol 2006; 30: 576–580
- Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. Br Med J 2002; 325: 1332–1333
- Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacol 2001; 25: 871–880
- Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo controlled clinical trials. Hum Psychopharmacol 2005; 20: 327–341
- Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005; 27: 1126–1143
- Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003; 31: 1142–1150
- Mandrioli R, Mercolini L, Cesta R, Fanali S, Amore M, Raggi MA. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. J Chromatogr B 2007; 856: 88–87
- Mercolini L, Mandrioli R, Cazzolla R, Amore M, Raggi MA. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid–phase extraction procedure. J Chromatogr B 2007; 856: 81–87
- Pascale P, Oddo M, Pacher P, Augsburger M, Liaudet L. Severe rhabdomyolysis following venlafaxine overdose. Ther Drug Monit 2005; 27: 562–564
- Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237–1244
- Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006; 7: 373–385
- Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40: 161–167
- Sweetman SC. Martindale-The Complete drug reference34th edition. Pharmaceutical Press, London 2005; 261
- Thase ME, Tran PV, Wietse C, Pangallo BA, Mallinckrodt C, Detke NJ. Cardiovalscular Profile of Duloxetine, a dual reuptake inhibitor of serotonin and norepineohrine. J Clin Psychopharmacol 2005; 25: 132–140